VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN. International Journal of Pharmaceutical Sciences and Drug Research, [S. l.], v. 9, n. 5, p. 224–227, 2017. DOI: 10.25004/IJPSDR.2017.090504. Disponível em: https://ijpsdronline.com/index.php/journal/article/view/562.. Acesso em: 24 oct. 2025.